Satellos Bioscience Inc. (NASDAQ:MSLE – Free Report) – HC Wainwright decreased their Q3 2026 earnings estimates for Satellos Bioscience in a report issued on Monday, August 17th. HC Wainwright analyst A. He now anticipates that the company will post earnings per share of ($0.43) for the quarter, down from their prior forecast of ($0.36). HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Satellos Bioscience’s current full-year earnings is ($1.85) per share. HC Wainwright also issued estimates for Satellos Bioscience’s Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.92) EPS, Q1 2027 earnings at ($0.43) EPS, Q2 2027 earnings at ($0.47) EPS, Q3 2027 earnings at ($0.49) EPS, Q4 2027 earnings at ($0.51) EPS, FY2027 earnings at ($1.89) EPS, FY2028 earnings at ($1.88) EPS, FY2029 earnings at ($0.88) EPS and FY2030 earnings at $0.86 EPS.
Several other equities analysts have also issued reports on the company. Guggenheim assumed coverage on Satellos Bioscience in a report on Tuesday, April 28th. They issued a “buy” rating and a $23.00 target price for the company. Canaccord Genuity Group upgraded Satellos Bioscience to a “moderate buy” rating in a report on Thursday, May 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a research report on Friday, August 7th. Wells Fargo & Company set a $18.00 price objective on Satellos Bioscience in a research note on Thursday, July 9th. Finally, Wall Street Zen raised Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.75.
Satellos Bioscience Stock Performance
Satellos Bioscience stock opened at $9.81 on Wednesday. Satellos Bioscience has a 52 week low of $4.91 and a 52 week high of $13.39. The business’s 50 day moving average price is $8.35. The company has a market cap of $204.44 million, a PE ratio of -5.11 and a beta of 1.51.
Satellos Bioscience (NASDAQ:MSLE – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.18).
Hedge Funds Weigh In On Satellos Bioscience
A hedge fund recently raised its stake in Satellos Bioscience stock. Stonepine Capital Management LLC boosted its stake in shares of Satellos Bioscience Inc. (NASDAQ:MSLE – Free Report) by 391.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 491,624 shares of the company’s stock after acquiring an additional 391,624 shares during the quarter. Satellos Bioscience accounts for about 2.0% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 16th largest holding. Stonepine Capital Management LLC owned approximately 2.36% of Satellos Bioscience worth $3,723,291,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Satellos Bioscience News Summary
Here are the key news stories impacting Satellos Bioscience this week:
- Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $18.00 price target for Satellos Bioscience. The target implies substantial upside from the recent $9.81 reference price, indicating that the analyst still sees significant long-term value in the company’s pipeline and growth prospects. Satellos Bioscience Earns Buy Rating from HC Wainwright
- Negative Sentiment: HC Wainwright lowered EPS estimates across multiple periods, including Q3 2026 to $(0.43) from $(0.36), FY2026 to $(1.92) from $(1.60), and FY2027 to $(1.89) from $(1.76). Forecasts were also reduced for 2027–2030, with projected FY2030 profit lowered to $0.86 per share from $0.93. The revisions suggest higher expected losses and a slower path to profitability, which can weigh on a development-stage biotechnology stock.
- Negative Sentiment: The company remains loss-making, with analysts expecting a current-year loss of approximately $(1.85) per share. Satellos also previously reported quarterly EPS of $(0.56), missing the $(0.38) consensus estimate, reinforcing concerns about ongoing cash needs and execution risk.
About Satellos Bioscience
Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.
Featured Stories
- Five stocks we like better than Satellos Bioscience
- Speed Sells: Cerebras Cracks the Silicon Ceiling
- Amid Legal Risks, This Company Is Still Rated a Buy
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
Receive News & Ratings for Satellos Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Satellos Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
